Ralliant (NYSE:RAL) Price Target Cut to $51.00 by Analysts at Citigroup

Ralliant (NYSE:RAL) had its target price reduced by Citigroup from $61.00 to $51.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently issued reports on RAL. Oppenheimer decreased their target price on Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday. Royal Bank Of Canada dropped their price target on Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday. Morgan Stanley reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Ralliant in a research note on Friday. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Friday. Finally, Truist Financial cut their price target on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.30.

Ralliant Stock Performance

Shares of RAL opened at $39.50 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 0.84 and a quick ratio of 1.03. The firm’s 50 day moving average is $51.52 and its 200-day moving average is $46.72. Ralliant has a 12-month low of $37.27 and a 12-month high of $57.02. The stock has a market capitalization of $4.46 billion and a P/E ratio of 31.10.

Ralliant (NYSE:RAL) last issued its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The business had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Ralliant’s dividend payout ratio is currently 15.75%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RAL. Danske Bank A S acquired a new stake in shares of Ralliant during the 4th quarter valued at $25,000. Allworth Financial LP increased its stake in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant during the fourth quarter worth $26,000. Manchester Capital Management LLC acquired a new stake in Ralliant during the second quarter valued at $29,000. Finally, Westfuller Advisors LLC purchased a new position in Ralliant in the third quarter valued at about $26,000.

Key Headlines Impacting Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Analyst upgrades: Vertical Research upgraded Ralliant from “hold” to “buy” with a $45 price target, which supports near‑term upside expectations. The Fly: Vertical Research upgrade
• Positive Sentiment: Citigroup maintained a “buy” rating (but trimmed its PT to $51 from $61), which still implies meaningful upside and likely helped calm some selling pressure. Benzinga: Citigroup note
• Positive Sentiment: Quarterly results modestly beat: Q4 EPS of $0.69 (vs. $0.67 est.) and revenue of ~$554.6M (vs. $543M est.), showing underlying operational resilience despite the one‑time items. MarketBeat: Q4 results
• Neutral Sentiment: Company set 2026 revenue target of $2.1B–$2.2B (roughly in line with consensus), which supports the topline outlook but is tempered by other items below. BusinessWire: FY2026 outlook
• Negative Sentiment: Material non‑cash charge: the company recorded a $1.4B goodwill impairment in its Test & Measurement segment (EA Elektro‑Automatik), producing a large reported net loss and triggering the recent sharp selloff. MarketWatch: $1.4B impairment
• Negative Sentiment: Multiple law‑firm investigations and investor notices (Holzer & Holzer, Johnson Fistel, Block & Leviton) are underway into the impairment and disclosures, adding legal/exec‑risk uncertainty. GlobeNewswire: Investor alerts
• Negative Sentiment: Shares recently hit an all‑time low after the impairment and heavy losses were disclosed, which can pressure sentiment until clarity on write‑ups, integration and legal outcomes emerges. InsiderMonkey: All‑time low coverage

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.